<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04578301</url>
  </required_header>
  <id_info>
    <org_study_id>PERSEVERE</org_study_id>
    <nct_id>NCT04578301</nct_id>
  </id_info>
  <brief_title>Predicting Acute-on-Chronic Liver Failure After Surgical Intervention in Chronic Liver Disease</brief_title>
  <acronym>PERSEVERE</acronym>
  <official_title>Predicting Acute-on-Chronic Liver Failure After Surgical Intervention in Chronic Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, observational study to define precipitants and predictors of development of&#xD;
      Acute-on-Chronic Liver Failure (ACLF) after surgical interventions, allowing to develop a&#xD;
      risk stratification for elective procedures in cirrhotic patients. As well as identifying&#xD;
      molecular mechanisms of post-interventional ACLF and thus preparing the ground for&#xD;
      development of new therapeutic approaches.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Acute-on-chronic liver failure (ACLF) is a recently discovered syndrome, which is&#xD;
      understood as an acute deterioration of decompen-sated liver cirrhosis. It is defined on the&#xD;
      basis of organ failure(s) and associated with high short-term mortality. ACLF is caused by a&#xD;
      precipi-tating event that results in excessive systemic inflammation. ACLF is mostly&#xD;
      precipitated and associated with bacterial infections but 40-50% of the underlying cause is&#xD;
      unclear. Surgery, with or without liver involvement, has been defined as such a precipitating&#xD;
      event. It is long known, that surgery in liver cirrhotic patients, depending on stage of&#xD;
      cirrhosis as well as on type of surgery, bears a great risk but is still in-evitable in some&#xD;
      cases. Child-Turquotte Score has been used for risk stratification of postoperative&#xD;
      mortality. The development and out-come of ACLF after surgical interventions have not been&#xD;
      characterized yet. In addition, underlying causes as well as molecular mechanism leading to&#xD;
      ACLF after surgical intervention have not been identified. The aim of this trial is to&#xD;
      further prospectively investigate patients with cirrhosis undergoing surgery to identify&#xD;
      clinical markers and molecular mechanisms involved in development of ACLF.&#xD;
&#xD;
      Objectives: Defining precipitants and predictors of development of ACLF after surgical&#xD;
      interventions, allowing to develop a risk stratification for elective procedures in cirrhotic&#xD;
      patients.&#xD;
&#xD;
      Identifying molecular mechanisms of post-interventional ACLF and thus preparing the ground&#xD;
      for development of new therapeutic approaches.&#xD;
&#xD;
      Study design: Prospective, observational study. Patients will be screened according&#xD;
      inclusion/exclusion criteria. After informed consent sample processing will be possible from&#xD;
      max. 1 week before scheduled surgery.&#xD;
&#xD;
      Primary endpoints: Development of ACLF within 28 and 90 days after visceral or non-visceral&#xD;
      surgery in patients with portal hypertension (liver cirrhosis and idiopathic non-cirrhotic&#xD;
      portal hypertension)&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
        1. Mortality at 1 month, 3 months and 1 year.&#xD;
&#xD;
           Following endpoints will be evaluated:&#xD;
&#xD;
           &quot; Time to death and mortality (overall and surgery-related) &quot; Time to and rate of&#xD;
           unplanned rehospitalizations after surgery &quot; Any Infection and differentiated by site of&#xD;
           infection (SBP, pneumonia, urinary tract infection, blood stream infection, Clostridium&#xD;
           difficile-associated enterocolitis &quot; Postsurgical acute hepatic decompensation and ACLF&#xD;
&#xD;
        2. To assess the changes in the intestinal microbiota in both groups and evaluate its&#xD;
           effect on the primary endpoint.&#xD;
&#xD;
        3. To assess the potential socioeconomic impact.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 22, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Episodes of Acute-on-Chronic Liver Failure (ACLF)</measure>
    <time_frame>90 days</time_frame>
    <description>Development of ACLF after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1-year mortality</measure>
    <time_frame>12 months</time_frame>
    <description>Death after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episodes of Acute Decompensation</measure>
    <time_frame>12 months</time_frame>
    <description>Acute hepatic Decompensation after Surgery</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Intestinal Microbiota</measure>
    <time_frame>12 months</time_frame>
    <description>Intestinal Microbiota will be assessed in stool samples.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Portal Hypertension</condition>
  <condition>Surgery</condition>
  <condition>Acute-On-Chronic Liver Failure</condition>
  <condition>Non-Cirrhotic Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>Surgery</arm_group_label>
    <description>Patients with and without liver cirrhosis undergoing surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention</intervention_name>
    <description>No Intervention</description>
    <arm_group_label>Surgery</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, urine, stool and tissue samples from surgical specimens&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with and without liver cirrhosis and/or portal hypertension undergoing elective or&#xD;
        emergency surgical intervention.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female adult (≥18 years) patient&#xD;
&#xD;
          -  With or without liver cirrhosis (diagnosed either histologically or by a combination&#xD;
             of clinical, laboratory and radiological signs)&#xD;
&#xD;
          -  Or Non-cirrhotic portal hypertension&#xD;
&#xD;
          -  Non-pregnant, non-lactating females&#xD;
&#xD;
          -  Ability to understand the patient information and to personally sign and date the&#xD;
             informed consent to participate in the study&#xD;
&#xD;
          -  The patient is co-operative and available for the entire study&#xD;
&#xD;
          -  Provided written informed consent&#xD;
&#xD;
          -  Indication for surgical intervention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Patients undergoing surgery as form of palliative cancer therapy&#xD;
&#xD;
          -  Presence or history of severe extra-hepatic diseases&#xD;
&#xD;
          -  HIV-positive patients&#xD;
&#xD;
          -  Previous liver or other transplantation&#xD;
&#xD;
          -  Patients with acute or subacute liver failure without underlying cirrhosis&#xD;
&#xD;
          -  Patients who decline to participate&#xD;
&#xD;
          -  Physician´s denial (e.g. the investigator considers that the patient will not follow&#xD;
             the protocol scheduled)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Praktiknjo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bonn</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Praktiknjo, MD</last_name>
    <phone>+4922828716375</phone>
    <email>michael.praktiknjo@ukbonn.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Johannes Chang, MD</last_name>
    <email>johannes.chang@ukbonn.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Praktiknjo, MD</last_name>
      <phone>+49228 28715770</phone>
      <email>michael.praktiknjo@ukbonn.de</email>
    </contact>
    <contact_backup>
      <last_name>Johannes Chang, MD</last_name>
      <phone>+49228 28715770</phone>
      <email>johannes.chang@ukbonn.de</email>
    </contact_backup>
    <investigator>
      <last_name>Nina Böhling, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 22, 2020</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>Michael Praktiknjo</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>ACLF</keyword>
  <keyword>Acute-On-Chronic Liver Failure</keyword>
  <keyword>Liver Cirrhosis</keyword>
  <keyword>Portal Hypertension</keyword>
  <keyword>Surgery</keyword>
  <keyword>Non-Cirrhotic Portal Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

